Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neuroblastoma × Fenretinide × Clear all

Phase

Status

Completed 3 Terminated 1 No longer available 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Head and Neck Neoplasms 2 Waldenstrom Macroglobulinemia 1 Ovarian Neoplasms 1 Neuroblastoma 1 Mouth Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 6 thymoglobulin 4 fludarabine phosphate 4 fludarabine 4 Topotecan 4 Temozolomide 4 Melphalan 4 Isotretinoin 4 Irinotecan 4 Etoposide 4 ribociclib 3 Thiotepa 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Busulfan 3 Bone Marrow Transplantation 3 Antilymphocyte Serum 3 temsirolimus 2 aldesleukin 2 Vincristine 2 Stem Cell Transplantation 2 Peripheral Blood Stem Cell Transplantation 2 Nivolumab 2 Interleukin-2 2 Flow Cytometry 2 Doxorubicin 2 Deferasirox 2 venetoclax 1 vandetanib 1 robatumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02163356 2022-03-31

SPOC2013-001

South Plains Oncology Consortium

Phase 1 Terminated

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡